Navigation Links
Drug Makers Withdraw Cough, Cold Meds for Infants
Date:10/11/2007

Move comes as U.S. regulators scrutinize safety of products linked to dozens of deaths

THURSDAY, Oct. 11 (HealthDay News) -- Leading drug makers announced a voluntary withdrawal Thursday of oral cough and cold medicines marketed for use in infants.

The move affects only "infant" oral medicines, not those intended and labeled for use in children age 2 and older. And it comes as U.S. regulators review the products' safety, following reports of dozens of deaths since 1969.

"The reason the makers of over-the-counter, oral cough and cold medicines for infants are voluntarily withdrawing these medicines is that there have been rare patterns of misuse leading to overdose recently identified, particularly in infants, and safety is our top priority," Linda A. Suydam, president of the Consumer Healthcare Products Association (CHPA), said in a prepared statement.

According to the CHPA, the cough and cold medicines that are being withdrawn are:

  • Dimetapp(R) Decongestant Plus Cough Infant Drops,
  • Dimetapp(R) Decongestant Infant Drops,
  • Little Colds(R) Decongestant Plus Cough,
  • Little Colds(R) Multi-Symptom Cold Formula,
  • PEDIACARE(R) Infant Drops Decongestant (containing pseudoephedrine),
  • PEDIACARE(R) Infant Drops Decongestant & Cough (containing pseudoephedrine),
  • PEDIACARE(R) Infant Dropper Decongestant (containing phenylephrine),
  • PEDIACARE(R) Infant Dropper Long-Acting Cough,
  • PEDIACARE(R) Infant Dropper Decongestant & Cough (containing phenylephrine),
  • Robitussin(R) Infant Cough DM Drops,
  • Triaminic(R) Infant & Toddler Thin Strips(R) Decongestant,
  • Triaminic(R) Infant & Toddler Thin Strips(R) Decongestant Plus Cough,
  • TYLENOL(R) Concentrated Infants' Drops Plus Cold,
  • TYLENOL(R) Concentrated Infants' Drops Plus Cold & Cough.

Last month, U.S. health experts urged the federal Food and Drug Administration to consider banning the sale of over-the-counter cough and cold medicines for young children. The recommendation, from FDA safety officials, would apply to decongestant use in children under 2, and antihistamines in those younger than 6, according to FDA documents.

An FDA advisory panel is scheduled to consider the recommendation during a meeting on Oct. 18 and 19, and will then offer an opinion to the full agency. The FDA typically follows the recommendations of its advisory boards but is not required to do so.

In the safety review released Sept. 28, the FDA experts recommended that all infant cough and cold products be removed from the market. They also recommended that the sizes of the droppers, cups and syringes packaged with products be standardized to reduce the possibility of confusion and overdose, The New York Times reported.

An FDA review of records filed with the agency between 1969 and September 2006 found 54 reports of deaths in children associated with decongestant medicines made with pseudoephedrine, phenylephrine or ephedrine. It also found 69 reports of deaths associated with antihistamine medicines containing diphenhydramine, brompheniramine or chlorpheniramine, the Associated Press reported.

Most of the deaths were children younger than 2.

The Consumer Healthcare Products Association, which represents makers of over-the-counter medicines, said it and its member companies have put forth recommendations to the FDA to strengthen the labels on all oral OTC children's cough and cold medicines from "ask a doctor" before using to "do not use" in children under 2 years of age.

More information

To learn more about the voluntary withdrawal, visit the Consumer Healthcare Products Association.



SOURCES: Oct. 11, 2007, prepared statement, Consumer Healthcare Products Association, Washington, D.C.; Sept. 28, 2007, U.S. Department of Health and Human Services report, The Food and Drug Administration's Oversight of Clinical Trials; The New York Times; Associated Press


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Researchers identify the early makers of Neonatal Sepsis
2. Epilepsy Patients Could Benefit From Pacemakers
3. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
4. Stem Cells Could Replace Electronic Pacemakers
5. Lawmakers alerted on new tobacco control policies by research team
6. Chocolate makers to be health wise and urge consumers to be too!
7. Drug Makers Banned From Providing Gifts To Doctors
8. Lawsuit Against Sunscreen Makers For False Claims of Protection Against Skin Cancer
9. Sensing The Health Hazard MP3 Makers Tone Down The Volume
10. Reliability of Pacemakers and Defibrillators to be Improved
11. Food Makers Pressurized to Reduce Salt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted ... 1:00 pm ET. This conference discusses strategies to prevent readmissions in light of ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
(Date:3/29/2017)... ... 2017 , ... Wells Pharmacy Network, a proud A4M Platinum ... World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO of ... in the training of physicians, scientists, and members of the public on anti-aging ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets ... Market Size & Forecast By Type (Insource IONM, Outsource IONM), ... report to their offering. ... The global Intraoperative Neuromonitoring (IONM) market ... intraoperative neuromonitoring market is anticipated to witness significant growth in ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Global ... ... aesthetic devices market to grow at a CAGR of 8.12% during ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:3/29/2017)... 29, 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused ... today announced that Carmine N. Stengone , president and chief ... Needham & Company 16 th Annual Healthcare Conference on Wednesday, ... the Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology: